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A B S T R A C T
The objective of this pilot study was to examine the usefulness of limbal autograft
transplantation (LCAT) in the treatment of recurrent pterygium. Eleven eyes with ad-
vanced recurrent pterygium underwent LCAT. All eyes were previously treated at least
two times either by simple excision (10) or conjunctival rotation autograft (1). In two
eyes (18.18%) symblepharon was present at the time of surgery, therefore LCAT was
combined with amniotic membrane transplantation. Limbal-conjunctival autograft
was taken from supero-lateral part of the same eye and transferred to the area where
pterygium was excised. No intraoperative complications occurred. In ten eyes (90.9%) no
pterygium recurrence was recorded during the follow-up time, and one (9.1%) recur-
rence was recorded after 5 months. In two eyes with combined symblepharon formation
remission of both pterygium and symblepharon growth was obtained. LCAT proved to
be a promising and safe procedure in recurrent pterygium treatment.
Introduction
Pterygium is caused by fibrovascular
overgrowth or extension of connective tis-
sue from the bulbar conjunctiva onto the
cornea. As pterygium advances, it may
induce irregular astigmatism and cause
decrease in visual acuity. When vision is
affected or the symptoms become more
bothersome, excision of the pterygium is
indicated. Recurrence rate after primary
excision rises up to 50%. Various adjunc-
tive treatment modalities have been ap-
plied in order to reduce the recurrence
rate. Beta radiation has been used effec-
tively to reduce the rate of recurrence but
this procedure has many complications
such as cataract formation, corneal and
stromal thinning, ulceration and kera-
titis sicca1. Both mitomycin-C and co-
njunctival autografts have recently be-
come popular as adjuncts in preventing
the recurrence of pterygium2. Argon laser
can also be used to prevent recurrence of
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pterygium. Laser burns (50-m spot size)
are made in the limbus in four parallel
rows, with care taken to treat all neo-
vascular fronds1. Conjunctival autograft
transplantation, popularized by Kenyon
et al in 1985, is another very effective
method in managing pterygia to prevent
recurrences3. The conjunctiva from the
uninvolved or the same eye is used to
cover the defect caused by the pterygium
excision. The common problem after all
these procedures is pterygium recurren-
ce. Recurrence rate increases when men-
tioned surgical techniques for primary
pterygium are applied for the second
time.
Recently, limbal-conjunctival auto-
graft transplantation has been used in re-
current pterygium treatment. The limbal
zone is the rim of cornea approximately
0.5 mm wide that abuts against the
sclera4. In order to understand ocular
surface disorders, Noel Rice emphasized
the importance of limbal stem cells that
are vital for normal corneal epithelial
regeneration5. Recently, it has been pro-
posed that limbal stem cells play an
important role in the pathogenesis of pte-
rygium6,7.
Patients and Methods
Eleven eyes of eleven patients with
advanced recurrent pterygium under-
went limbal-conjunctival autograft trans-
plantation (LCAT) after pterygium exci-
sion. Patients were operated in a period
between November 1999 and July 2000
by the same surgeon. The mean age of pa-
tients was 48 (range 35 to 60). Six pa-
tients were men and five were women.
Ten eyes were previously operated at
least two (up to 8) times by simple exci-
sion and one eye by conjunctival rotation
autograft. Pterygium growth over the
cornea was 3 mm or more (Table 1).
A retrobulbar block with lidocaine 2%
was used in all cases. Pterygium was
completely resected from the cornea and
the body of the pterygium was dissected
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1 35 Excision (2) 3  4 Normal 0.3
2 58 Excision (3) 3.5  4 Normal 0.4
3 40 Excision (2) 3  3 Normal 0.5
4 43 Excision (2) 4.5  5.5 Normal 0.3
5 52 Excision (2) 4  4.5 Normal 0.2




5  5 Normal 0.2




9 49 Excision (3) 5  5 Normal 0.2
10 50 Excision (4) 5.5  4 Normal 0.2




* BCVA – Best corrected visual acuity
and excised by conjunctival scissors. The
abnormal scarring tissue on the corneal
surface was polished. Cautery was used
to control bleeding. A limbal-conjunctival
autograft was taken from the superola-
teral side of the same eye and transferred
to the area where pterygium was excised.
Autografts contained 0.5 mm of limbal
area and 5–10 mm of adjacent bulbar
conjunctiva depending on pterygium size.
The conjunctival graft was sutured to the
recipient bed with an interrupted 8–0
Vicryl and limbal part of the graft was se-
cured with two 10–0 nylon sutures.
In two eyes (18.18%) symblepharon
was present at the time of surgery; there-
fore LCAT was combined with amniotic
membrane transplantation. In these
eyes, besides pterygium removal, all the
symblepharons were released. Contrac-
ted subconjunctival scarred tissue was
dissected from the conjunctiva and scle-
ra. Defected tissue was replaced with ad-
equate piece of amniotic membrane. An-
other large amniotic membrane was
placed over the entire cornea and sutured
to the recipient conjunctiva with inter-
rupted 10–0 nylon sutures. Sutures were
removed after amniotic membrane resor-
ption. Postoperative therapy included an-
tibiotic (tobramycin) and corticosteroid
drops (dexamethason-neomycin) in all
eyes. Patients were examined every day
during the first postoperative week, on
postoperative days 14, 28 and every
month thereafter. The follow-up period
ranged from 3 to 7 months (mean 5.9).
Preparation and storage of human
amniotic membrane
Amniotic membrane is obtained under
sterile conditions after elective cesarean
delivery from a seronegative donor (HIV,
HBV, and HCV negative). Under lami-
nar-flow placenta is first washed free of
blood clots with balanced saline solution
containing 50 g/ml of penicillin, 50 g/ml
of streptomycin, 100 g/ml of neomycin
and 2.5 g/ml of amphotericin B. Am-
niotic membrane is separated from the
rest of the chorion and rinsed again with
the balanced saline solution containing
antibiotics. The membrane is then flat-
tened onto a nitrocellulose paper (3  4
cm), with the epithelium/basement mem-
brane surface up, and sutured with the
nonresorptive nylon. Amniotic membrane
is stored in a sterile vial containing tissue
culture (InOsol) and glycerol at a ratio of
1: 1 at – 80 °C. Before use, amniotic mem-
brane is defrosted by warming the vial at
the room temperature for 10 minutes.
Results
No intraoperative complications oc-
curred. During the first postoperative
week patients had mild symptoms of
slight ocular pain, foreign body sensation,
lacrimation and photophobia. Two co-
njunctival grafts (18.18%) showed signifi-
cant edema in the first few postoperative
days, but finally disappeared without ex-
cessive scar formation. Donor area healed
without any complications. In 10 eyes
(90.9%) no pterygium recurrence was re-
corded during the follow-up. In one eye
(9.1%) pterygium recurrence was recor-
ded after 5 months. In two eyes with
pterygium and symblepharon formation,
normal eye movements and pterygium
remission were achieved. No visual acu-
ity loss was noted. Best-corrected visual
acuity (BCVA) improved in 10 eyes
(90.9%) while in one eye (9.1%) it re-
mained unchanged. BCVA improved
three Snellen lines in 4 eyes (36.36%),
two in 4 eyes (36.36%) and one in 2 eyes
(18.18%) (Table 2).
Discussion
Pterygium is a worldwide degenera-
tive corneal disease with a multifactorial
etiology. Its incidence is higher in tropical
and subtropical countries where prolon-
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ged exposure to intense solar radiation is
common. According to some recently pub-
lished data the initial biologic event in
pterygium pathogenesis is limbal stem
cells alteration due to chronic ultraviolet
light exposure5–8.
Although many surgical approaches
have been developed, the main problem of
pterygium treatment is the recurrence
rate, which has been estimated as high as
30 to 70%9. The increased rate of ptery-
gium recurrence has been recorded in
younger patients10,11. Recurrent pterygium
is more difficult to control, and various
treatment modalities have been propos-
ed, including radiotherapy, antimetabo-
lite or antineoplastic drugs, conjunctival
or limbal autografts9,12. Limbal auto-
grafts have been used in treating corneal
diseases with stem cells deficiency, such
as chemical or thermal burns, aniridia,
the Stevens-Johnson syndrome, ocular
pemphigoid, conjunctival squamous cell
carcinoma, recurrent or advanced ptery-
gia and contact lens associated ocular
surface abnormality. Limbal autografts
have been used successfully to correct
limbal dysfunction, acting as a barrier
against conjunctival invasion of the cor-
nea and supplying stem cells of the cor-
neal epithelium13–16.
Although the pathogenesis of ptery-
gium is still unclear, according to some
authors, destruction of limbal stem cells
can result in pterygium formation6,7. For
this reason LCAT can be recommended as
an ideal surgical technique for treating
either primary or recurrent pterygium.
Using this technique some complications
occurring when using radiation or mi-
tomycin C can be avoided. These may in-
clude scleral ulceration and necrosis, sec-
ondary glaucoma, corneal perforation,
cataract formation, iritis and irreversible
damage to basal epithelial and limbal
stem cells17. Possible complications of
LCAT are transient graft edema, corneo-
scleral dellen, graft retraction, epithelial
inclusion cysts, Tenon’s granulomas, ne-
crosis or retraction of the graft, and
pseudopterygium formation on the donor
site18,19.
Another significant problem with re-
current pterygium after multiple surger-
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1 LCAT* 3 0.5 No Normal
2 LCAT 6 0.6 No Normal
3 LCAT 7 0.8 No Normal
4 LCAT 6 0.4 No Normal
5 LCAT 5 0.4 No Normal
6 LCAT 7 0.6 No Normal
7 LCAT 5 0.5 No Normal
8 LCAT + AMT** 7 0.3 No Normal
9 LCAT 6 0.4 No Normal
10 LCAT 6 0.2 Yes Normal
11 LCAT + AMT 7 0.2 No Normal
* LCAT- Limbal-conjunctival autograft transplantation
** AMT- Amniotic membrane transplantation
*** BCVA-Best corrected visual acuity
ies is conjunctival fornix shortening or
symblepharon. To treat this complicated
disorder, it is necessary to reconstruct the
limbal barrier as well as to suppress the
subconjunctival fibrosis16. Suppression of
subconjunctival fibrosis is very important
since in those cases patients show limited
ocular movements. However, this cannot
be achieved by conjunctival graft alone.
For this reason, in two of our patients
with pterygium and symblepharon for-
mation the LCAT was combined with
amniotic membrane transplantation and
remission of both pterygium and sym-
blepharon was achieved. In those cases
amniotic membrane transplantation ap-
pears to be effective in restoring ocular
motility. The transplanted amniotic
membrane is covered by conjunctival epi-
thelium and it serves as a new substrate
for proper epithelialization. It can be
used to cover areas of almost any size3,16.
According to some published data20–23,
the use of limbal reconstruction in ptery-
gium treatment reduces the recurrence
rate but it still does not completely elimi-
nate it. There is a large variability of re-
currence rates in different studies. Starc
and collaborators24 treated 40 eyes with
primary and 18 eyes with recurrent pte-
rygium using LACT. The postoperative
follow-up ranged from 2 to 26 months
with an average of 13 months. The over-
all recurrence rate was 31% (22.5% in pri-
mary and 50% in recurrent pterygium).
On the other hand, Shimazaki and co-
workers23 treated eleven patients with
recurrent and 16 with advanced ptery-
gium using this surgical technique. The
average follow-up period was 10.5 months
and the only slight recurrence was noted
in 2 eyes (7.4%). Even in these instances
invasion of subconjunctival tissue was
limited to less than 1 mm and there was
no need for additional surgery. The rea-
sons for this disproportion in treatment
results are unclear but possibly reflect
differences in definition of recurrence,
surgical technique and expertise, and pa-
tients’ demographics.
Our study included eleven patients
with advanced recurrent pterygium. All
cases were severe, with a minimum of
two recurrences. Particularly challenging
were two patients with pterygium and
symblepharon who were both treated
with LCAT and amniotic membrane
transplantation. During the follow-up,
pterygium recurrence occurred after 5
months in only one eye (9.1%).
Thus, irrespective of the limited num-
ber of cases included in the study, we are
of the opinion that LCAT is a safe and
promising treatment for recurrent pte-
rygium. The inclusion of limbal tissue in
conjunctival autografts following ptery-
gium excision appears to be essential for
ensuring the low recurrence rates. As
previously reported, almost all recurren-
ces are seen by the end of the first postop-
erative year10,11,24. Longer follow-up pe-
riod and larger number of patients is
needed to determine the real efficacy of
this surgical technique.
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LIMBALNA AUTOTRANSPLANTACIJA U TERAPIJI PTERIGIJA
S A @ E T A K
Cilj ove pilot studije bio je istra`iti korisnost limbalne autotransplantacije u terapiji
recidiviraju}eg pterigija. Limbalna autotransplantacija napravljena je u 11 o~iju s uzna-
predovalim recidiviraju}im pterigijem. Sve o~i prethodno su lije~ene najmanje dva puta
jednostavnom ekscizijom (10) ili konjunktivalnim rotiraju}im autotransplantatom (1).
U vrijeme operacije simblefaron je bio prisutan u dva oka (18.8%) pa je limbalna auto-
transplantacija kombinirana s transplantacijom amnijske membrane. Limbalno-konjun-
ktivalni autotransplantat uziman je iz superolateralnog dijela oka i premje{ten u podru~je
gdje je isjecan pterigij. Intraoperativne komplikacije nisu zabilje`ene. Za vrijeme pra}enja
pacijenata u deset o~iju (90.9%) nije zabilje`eno recidiviranje pterigija, dok je u jednom
oku (9.1%) recidiviranje zabilje`eno 5 mjeseci postoperativno. U dva oka s kombini-
ranom simblefaronskom formacijom zabilje`ena je remisija i pterigija i simblefarona.
Limbalna autotransplantacija predstavlja obe}avaju}i i siguran postupak u terapiji
recidiviraju}eg pterigija.
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